Save time and jump to the most important pieces.
SC 13G/A - FutureTech II Acquisition Corp. (0001889450) (Subject)
SC 13G/A - FutureTech II Acquisition Corp. (0001889450) (Subject)
SC 13G - FutureTech II Acquisition Corp. (0001889450) (Subject)
4 - FutureTech II Acquisition Corp. (0001889450) (Issuer)
4 - FutureTech II Acquisition Corp. (0001889450) (Issuer)
4 - FutureTech II Acquisition Corp. (0001889450) (Issuer)
SCHEDULE 13G/A - FutureTech II Acquisition Corp. (0001889450) (Subject)
8-K - FutureTech II Acquisition Corp. (0001889450) (Filer)
10-K - FutureTech II Acquisition Corp. (0001889450) (Filer)
New York, New York, Dec. 04, 2024 (GLOBE NEWSWIRE) -- FutureTech II Acquisition Corp. (the "Company") (NASDAQ:FTII), today announced that it received an expected deficiency notification letter from the staff (the "Staff") of The Nasdaq Stock Market LLC ("Nasdaq") on November 27, 2024 (the "Notice"). The Notice indicated that the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1) as a result of its failure to timely file its Quarterly Report on Form 10-Q for the quarter ended September 30, 2024 (the "Q3 10-Q"), as described more fully in the Company's Form 12b-25 Notification of Late Filing filed with the Securities and Exchange Commission (the "SEC") on November 15, 2024. Th
-Longevity Biomedical, Inc. is focused on developing and acquiring new technologies spanning therapeutics, health monitoring and digital health solutions to become a leading provider of longevity-related products and services designed to increase the health span for the rapidly growing global aging population. -Late-stage, diversified pipeline of therapeutic candidates across ophthalmology, cardiovascular disease and soft tissue reconstruction and repair. -Near-term clinical milestones include Phase 3 start for LBI-201 for Ischemic stroke, Phase 2 data for LBI-101 for soft-tissue reconstruction, and Phase 2 start for LBI-001 in retinal vein occlusion. -Seasoned management team of m
New Rochelle, NY, May 17, 2023 (GLOBE NEWSWIRE) -- FutureTech II Acquisition Corp. (NASDAQ:FTIIU) (the "Company"), a blank check company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses, announced today that it caused to be deposited $1,150,000 into the Company's trust account for its public stockholders, representing $0.10 per public share, allowing the Company to extend by three months (from May 18, 2023 to August 18, 2023) the period of time the Company has to consummate its initial business combination (the "Extension"). The Extension is the second of two